SCHEMBL3166019

SCHEMBL3166019

Nc1nccc[n+]1[O-]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9355983 0.74 HDAC8 (0.37)
SCHEMBL3881120 0.70
SCHEMBL83774 0.70
SCHEMBL30159553 0.70
SCHEMBL27630930 0.70
SCHEMBL27274025 0.70
SCHEMBL19358691 0.70
SCHEMBL3825029 0.68 HDAC8 (0.33)
SCHEMBL1730333 0.68
SCHEMBL15772610 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116421507-A Hair-loss-preventing and hair-growing composition and application thereof 配方化妆品科技(广州)有限公司 2023-07-14 CN claimed
US-20050049232-A1 Composition LINDAU PAR (SE) 2005-03-03 US claimed
EP-1463483-A1 NEW COMPOSITION Ponsus Pharma AB (SE) 2004-10-06 EP claimed
US-20040116453-A1 Synthesis and methods of use pyrimidine analogues and derivatives SPECTRUM PHARMACEUTICALS, INC. 2004-06-17 US claimed
EP-1334103-A2 METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS Neotherapeutics, Inc. (US) 2003-08-13 EP claimed
EP-1334104-A2 METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS Neotherapeutics, Inc. (US) 2003-08-13 EP claimed
WO-2003055454-A1 NEW COMPOSITION PONSUS PHARMA AB (SE) 2003-07-10 WO claimed
US-20030055249-A1 Synthesis and methods of use of pyrimidine analogues and derivatives NEOTHERAPEUTICS, INC. 2003-03-20 US claimed
WO-2003007963-A1 PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES NEOTHERAPEUTICS, INC. (US) 2003-01-30 WO claimed
US-20020128264-A1 Methods for treatment of conditions affected by activity of multidrug transporters NEOTHERAPEUTICS, INC. 2002-09-12 US claimed
EP-0378255-B1 2-Aminopyrimidinone derivatives JANSSEN PHARMACEUTICA NV (BE) 1994-04-27 EP claimed
EP-0420707-B1 Compositions to be used to reduce hair-loss and to induce and stimulate its growth, containing derivatives of 2-aminopyrimidine 3-oxide and new compounds derived from 2-aminopyrimidine 3-oxide OREAL (FR) 1993-12-15 EP claimed
CN-1044099-A The 2-aminopyrimidinone derivatives JANSSEN PHARMACEUTICA NV (BE) 1990-07-25 CN claimed
CN-1044094-A 2-AMINOPYRIMIDINONE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 1990-07-25 CN claimed
EP-0378254-A2 2-Aminopyrimidinone derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1990-07-18 EP claimed
EP-0378255-A2 2-Aminopyrimidinone derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1990-07-18 EP claimed
US-4523015-A Process and nitroaminopyrimidone intermediates for histamine H2 -antagonists SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1985-06-11 US claimed
EP-0057546-A2 Sulfonylurea N-oxides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1982-08-11 EP claimed
EP-0004793-B1 2-NITRO AMINOPYRIMIDONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE TO PREPARE 2-AMINOPYRIMIDONE DERIVATIVES WHICH HAVE HISTAMINE H2-ANTAGONIST ACTIVITY SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1981-12-30 EP claimed
EP-0004793-A2 2-nitro aminopyrimidone derivatives, a process for their preparation and their use to prepare 2-aminopyrimidone derivatives which have histamine H2-antagonist activity SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-10-17 EP claimed